Camrelizumab and famitinib are projected to achieve global annual sales of $463 million and $108 million by 2031.

BERLIN -- The investigational tyrosine kinase inhibitor (TKI) zanzalintinib plus atezolizumab (Tecentriq) significantly ...

If approved in RCC, fruquintinib will be available for three indications, including endometrial and colorectal cancer.

Ivonescimab’s progression-free survival data bode well for an upcoming overall survival readout, according to Truist analysts ...

Ivonescimab combined with chemotherapy significantly improved progression-free survival (PFS) compared with Tevimbra ...

A multicenter Phase II clinical trial led by researchers at The University of Texas MD Anderson Cancer Center demonstrated significant tumor shrinkage and disease control in patients with advanced ...

A closely watched trial in Chinese patients is raising hope that ivonescimab will outperform Keytruda in a large global study ...

After upstaging Merck & Co.’s Keytruda as a monotherapy for patients with first-line non-small cell lung cancer (NSCLC) in ...

DURAVYU now in Phase 3 for the two largest, multi-billion-dollar retinal disease markets, wet AMD and DME with first patient dosing in pivotal ...

Phase II trial shows belzutifan effectively shrinks rare neuroendocrine tumors and improves symptoms, offering hope for ...